Patents by Inventor Yongkui Jing

Yongkui Jing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9718837
    Abstract: The present invention belongs to the field of medicinal technique, specifically relates to nitrogen-containing heterocyclic ring-substituted dihydroartemisinin derivatives and their optical isomers according to formula I or II; wherein substituent X, Y, R, R1, R2, R3 and R4 are as defined in the Description. The derivatives and compositions thereof can be prepared into clinically acceptable tablets, capsules, injections, ointments, etc., and thus have pharmaceutical uses in the treatment and/or prevention of cancers.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: August 1, 2017
    Assignee: Shenyang Pharmaceutical University
    Inventors: Linxiang Zhao, Dan Liu, Hang Zhong, Xuan Zhao, Yongkui Jing
  • Publication number: 20160009729
    Abstract: The present invention belongs to the field of medicinal technique, specifically relates to nitrogen-containing heterocyclic ring-substituted dihydroartemisinin derivatives and their optical isomers according to formula I or II; wherein substituent X, Y, r, R1, R2, R3 and R4 are as defined in the Description. The derivatives and compositions thereof can be prepared into clinically acceptable tablets, capsules, injections, ointments, etc., and thus have pharmaceutical uses in the treatment and/or prevention of cancers.
    Type: Application
    Filed: February 20, 2014
    Publication date: January 14, 2016
    Inventors: Linxiang Zhao, Dan Liu, Hang Zhong, Xuan Zhao, Yongkui Jing
  • Patent number: 8415505
    Abstract: The invention relates to 2-methylene-5-substituted-methylenecyclopentanone derivatives of formula I, and the use thereof. The derivatives of formula I as active components are useful for preparing a medicine for the treatment and/or prevention of cancer diseases such as breast cancer, lung cancer, colon cancer, rectal cancer, stomach cancer, prostate cancer, bladder cancer, uterus cancer, pancreatic cancer and ovary cancer. The active compounds of the invention may be used as an anticancer drug alone or used in combination with one or more other antitumor drugs. A combined therapy can be carried out by administrating each therapeutic component concurrently, subsequently or separately.
    Type: Grant
    Filed: February 10, 2009
    Date of Patent: April 9, 2013
    Assignee: Shenyang Pharmaceutical University
    Inventors: Linxiang Zhao, Jingli Wang, Zhenjun Bian, Rui Wang, Dan Liu, Yongkui Jing
  • Patent number: 8349835
    Abstract: The invention belongs to pharmaceutical field. The invention relates to the compounds according to Formula I, including their optically active forms, pharmaceutically acceptable salts or hydrates, and the pharmaceutical composition comprising thereof as active ingredient; uses in the preparation of vascular endothelial growth factor receptor tyrosine kinase inhibitors, and uses in the preparation of medicament for the treatment and/or prevention of cancer.
    Type: Grant
    Filed: February 10, 2009
    Date of Patent: January 8, 2013
    Assignee: Shenyang Pharmaceutical University
    Inventors: Linxiang Zhao, Jinling Lv, Rui Wang, Dan Liu, Yongkui Jing
  • Publication number: 20110183972
    Abstract: The invention belongs to pharmaceutical field. The invention relates to the compounds according to Formula I, including their optically active forms, pharmaceutically acceptable salts or hydrates, and the pharmaceutical composition comprising thereof as active ingredient; uses in the preparation of vascular endothelial growth factor receptor tyrosine kinase inhibitors, and uses in the preparation of medicament for the treatment and/or prevention of cancer.
    Type: Application
    Filed: February 10, 2009
    Publication date: July 28, 2011
    Applicant: SHENYANG PHARMACEUTICAL UNIVERSITY
    Inventors: Linxiang Zhao, Jinling Lv, Rui Wang, Dan Liu, Yongkui Jing
  • Publication number: 20110060054
    Abstract: The invention relates to 2-methylene-5-substituted-methylenecyclopentanone derivatives of formula I, and the use thereof. The derivatives of formula I as active components are useful for preparing a medicine for the treatment and/or prevention of cancer diseases such as breast cancer, lung cancer, colon cancer, rectal cancer, stomach cancer, prostate cancer, bladder cancer, uterus cancer, pancreatic cancer and ovary cancer. The active compounds of the invention may be used as an anticancer drug alone or used in combination with one or more other antitumor drugs. A combined therapy can be carried out by administrating each therapeutic component concurrently, subsequently or separately.
    Type: Application
    Filed: February 10, 2009
    Publication date: March 10, 2011
    Applicant: SHENYANG PHARMACEUTICAL UNIVERSITY
    Inventors: Linxiang Zhao, Jingli Wang, Zhenjun Bian, Rui Wang, Dan Liu, Yongkui Jing